Michael Gelband’s AtriCure ATRC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.42M Buy
+86,356
New +$2.43M 0.02% 755
2026
Q1
Sell
-8,966
Closed -$355K 1547
2025
Q4
$355K Buy
+8,966
New +$329K ﹤0.01% 1268
2024
Q4
Sell
-30,418
Closed -$853K 1514
2024
Q3
$853K Sell
30,418
-36,603
-55% -$902K 0.01% 1012
2024
Q2
$1.53M Buy
67,021
+5,504
+9% +$127K 0.01% 876
2024
Q1
$1.87M Sell
61,517
-14,338
-19% -$480K 0.01% 733
2023
Q4
$2.71M Buy
75,855
+40,739
+116% +$1.52M 0.02% 489
2023
Q3
$1.54M Sell
35,116
-729
-2% -$35.6K 0.01% 777
2023
Q2
$1.77M Sell
35,845
-50,340
-58% -$2.32M 0.01% 858
2023
Q1
$3.57M Buy
86,185
+63,764
+284% +$2.65M 0.03% 640
2022
Q4
$995K Buy
22,421
+7,958
+55% +$332K 0.01% 944
2022
Q3
$566K Sell
14,463
-42,353
-75% -$1.94M 0.01% 1323
2022
Q2
$2.32M Sell
56,816
-58,949
-51% -$2.79M 0.03% 721
2022
Q1
$7.6M Sell
115,765
-34,763
-23% -$2.25M 0.1% 262
2021
Q4
$10.5M Buy
+150,528
New +$10.9M 0.11% 213
2020
Q3
Sell
-77,498
Closed -$3.48M 1738
2020
Q2
$3.48M Buy
77,498
+6,356
+9% +$277K 0.09% 247
2020
Q1
$2.39M Buy
+71,142
New +$2.56M 0.13% 157

Other funds holding ATRC

Michael Gelband's ATRC Position: Q2 2026 in Review

Michael Gelband opened a new position in AtriCure (ATRC) in Q2 2026: 86,356 shares worth $2.42M. The stake represents 0.02% of the portfolio and ranks #755 among its holdings. This is a return to the name: Michael Gelband previously reported a position in ATRC as recently as Q4 2025.

Michael Gelband first reported a position in ATRC in Q1 2020 and has held it in 16 quarters since. The position peaked at $10.5M in Q4 2021. 250 funds tracked by Wall St. Rank hold ATRC as of Q2 2026.

  • Michael Gelband held 86,356 shares of AtriCure worth $2.42M as of Q2 2026.
  • AtriCure was a new Michael Gelband position in Q2 2026.
  • AtriCure made up 0.02% of Michael Gelband's portfolio in Q2 2026, its #755 holding.
  • Michael Gelband first reported a position in AtriCure in Q1 2020 and has held it in 16 quarters since.
  • Michael Gelband's AtriCure position peaked at $10.5M in Q4 2021.
  • 250 funds tracked by Wall St. Rank held AtriCure as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.